Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

  1. Home
  2. /Market

Signal category

Market Signals

Understand market structure changes, launch dynamics, and access shifts that affect asset and company valuations.

Pricing, access, demand, and commercialization trends that influence revenue outlooks and investment theses.

Score6.8

Signal

Alembic Pharmaceuticals Submits ANDA220639 for Review

Company

Alembic Pharmaceuticals

Category

Strategy

Therapeutic Area

Not specified

Action

Track

Strategymoderate signal

Alembic Pharmaceuticals Submits ANDA220639 for Review

Alembic Pharmaceuticals has submitted ANDA220639 for review with a standard review priority.

June 18, 2026Read signal →
Trial SummaryCLN

Phase III

Not specified

Status

Positive

Sponsor

AstraZeneca

Signal Score

8.2

Strategyhigh signal

AstraZeneca Reports Strong Q1 2026 Revenue Growth and Positive NME Readouts

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Competitive LandscapeCMP
DrugMOA / CompanyStage
HIV prevention marketDual Prevention PillLead

Focal Asset

HIV prevention market

Company

Dual Prevention Pill

Indication

Infectious Disease / HIV and Contraception

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

AstraZeneca reported a 13% increase in total revenue for Q1 2026, driven by strong product sales and positive readouts from new molecular entities (NMEs).

June 16, 2026Read signal →

Company

Eli Lilly

Asset

Foundayo

Indication

Obesity / Pharmacotherapy

Status

Under Review

Signal Score

8.4

Strategyhigh signal

CVS Caremark to cover Foundayo and Zepbound, enhancing access for obesity treatment

CVS Caremark will cover Foundayo starting June 1 and Zepbound from October 1, allowing eligible patients to pay as low as $25 monthly.

June 16, 2026Read signal →

Signal Score

8.2

Strategyhigh signal

South African HCPs Support Dual Prevention Pill but Highlight Key Challenges

Healthcare providers in South Africa support the Dual Prevention Pill (DPP) for HIV and pregnancy prevention but express concerns about daily dosing and side effects.

June 7, 2026Read signal →